Erasca (ERAS) AI Stock Analysis

• Market Cap: $5.07B
• Dividend Yield: N/A
• Average Volume (3M): 6.76M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: N/A
• EPS Growth: 45.66%
• Country: US
• Employees: 103
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 310,799,560
• 10 Day Avg. Volume: 8,687,046
• 30 Day Avg. Volume: 6,757,213
• PEG Ratio: 0.23
• Price to Book (P/B): 3.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.03
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.58K
• Enterprise Value/Ebitda: -44.55
• 1Y Price Target: $17.09
• Price Target Upside: -4.26% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -0.43
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $18.50 ▲(3.64% Upside)
• Action: Reiterated Date: 04/03/26
• Date: Action: Reiterated 04/03/26

The score is held back primarily by weak financial performance (no revenue, large ongoing losses and cash burn), partially offset by strong technical momentum and positive corporate events that extend liquidity runway and highlight clinical progress. Valuation signals remain constrained due to ongoing losses and lack of dividend support.

Positive Factors

Extended Cash Runway

An upsized public offering generated estimated net proceeds of ~$242.7M and cash of ~$341.8M as of Dec 31, 2025, extending runway into H1 2029. This multi-year liquidity reduces near-term financing pressure, allowing management to execute clinical programs and de-risk assets before needing additional capital.

Negative Factors

No Commercial Revenue

Erasca remains pre-commercial with no product sales, so it cannot fund operations from recurring revenue. Long-term viability depends on clinical success, milestone or partnership receipts, and capital markets access, creating a structural reliance on external financing until commercialization.

Erasca Business Overview & Revenue Model

Company Description

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK...

Read more

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK...

How the Company Makes Money

Erasca is a clinical-stage biotechnology company and, as such, it does not primarily generate recurring revenue from commercial product sales because it does not have any approved products for sale. Its reported revenue, when present, is typically...

Read more

Erasca is a clinical-stage biotechnology company and, as such, it does not primarily generate recurring revenue from commercial product sales because it does not have any approved products for sale. Its reported revenue, when present, is typically...

Erasca Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.11M	0.00	-3.73M	-2.64M	-829.00K
EBITDA	-128.30M	-153.28M	-121.31M	-240.16M	-121.94M
Net Income	-124.55M	-161.65M	-125.04M	-242.81M	-122.76M
Balance Sheet
Total Assets	396.15M	502.53M	395.30M	514.91M	501.42M
Cash, Cash Equivalents and Short-Term Investments	276.07M	298.31M	312.35M	435.62M	414.48M
Total Debt	47.14M	51.89M	55.86M	55.10M	18.79M
Total Liabilities	70.98M	79.03M	78.61M	103.06M	44.89M
Stockholders Equity	325.17M	423.50M	316.69M	411.85M	456.53M
Cash Flow
Free Cash Flow	-95.58M	-131.98M	-102.99M	-119.81M	-98.48M
Operating Cash Flow	-95.45M	-109.42M	-101.22M	-103.26M	-79.60M
Investing Cash Flow	100.42M	-156.62M	-91.22M	-71.08M	-64.59M
Financing Cash Flow	1.10M	240.70M	1.29M	98.08M	439.40M

Erasca Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ERAS, the sentiment is Positive. The current price of 17.85 is above the 20-day moving average (MA) of 15.85, above the 50-day MA of 14.28, and above the 200-day MA of 5.80, indicating a bullish trend. The MACD of 0.96 indicates Negative momentum. The RSI at 64.53 is Neutral, neither overbought nor oversold. The STOCH value of 71.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ERAS.

Erasca Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCAX	62 Neutral	$1.45B	-6.67	-32.49%	―	―	-103.95%
ERAS	57 Neutral	$5.07B	-8.47	-32.00%	―	―	45.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARCT	50 Neutral	$240.46M	-1.44	-27.43%	―	-41.53%	-11.32%
ARVN	48 Neutral	$676.71M	-9.53	-14.25%	―	―	―
OLMA	47 Neutral	$1.39B	-13.39	-42.90%	―	―	17.23%

Erasca Corporate Events